elsevi
inc
right
reserv
articl
updat
version
previou
edit
articl
charl
poser
volum
pp
elsevi
inc
overal
preval
diseas
vari
differ
region
globe
rang
kingwel
et
al
rosati
accord
estim
million
peopl
worldwid
suffer
multipl
sclerosi
ms
diseas
one
common
caus
neurolog
disabl
young
adult
suggest
variabl
follow
certain
pattern
greatli
depend
latitud
countri
figur
howev
epidemiolog
data
depict
diseas
vari
greatli
area
similar
latitud
eber
sadovnick
nevertheless
ms
preval
higher
northern
southern
europ
america
tabl
like
due
differ
ethnic
popul
ms
much
frequent
peopl
scandinavian
either
direct
indirect
descent
includ
american
northern
state
hand
preval
high
southern
countri
croatia
israel
kuwait
south
africa
great
differ
ms
preval
geograph
close
area
malta
sicilia
sardinia
diseas
extrem
rare
hindu
live
mumbai
uncommon
parsi
live
citi
almost
case
ms
report
north
south
american
indian
sami
lapp
eskimo
australian
aborigin
maori
melanesian
micronesian
polynesian
ms
also
extrem
rare
black
african
israel
good
paradigm
evalu
variabl
incid
ms
subpopul
geograph
region
similar
environment
condit
sinc
distinct
welldistinguish
ethnic
group
live
countri
new
immigr
arriv
countri
preval
ms
variabl
preval
ms
three
time
higher
jewish
arab
popul
diseas
also
three
time
frequent
askenazi
jew
compar
sefarad
origin
alter
et
al
arab
popul
region
ms
low
medium
rate
preval
rate
christian
arab
thrice
high
muslim
arab
suggest
differ
risk
factor
oper
two
subethn
group
alter
et
al
milo
kahana
siegel
et
al
karni
et
al
etiopathogenesi
ms
describ
diseas
unknown
etiolog
impli
involv
sever
factor
singl
caus
includ
genet
background
infecti
agent
hormon
environment
factor
complex
interplay
give
rise
immunemedi
attack
myelin
sheath
strike
differ
preval
similar
environ
strongli
suggest
import
role
genet
factor
famili
occurr
rate
ageadjust
risk
higher
sibl
children
risk
child
one
parent
suffer
ms
suffer
ms
secondand
thirddegre
rel
concord
monozygot
twin
adopt
offspr
nonbiolog
rel
increas
risk
sadovnick
indic
numer
studi
genet
marker
carri
intern
multipl
sclerosi
genet
consortium
et
al
date
secur
candid
region
identifi
associ
rather
weak
dyment
et
al
eber
sawcer
et
al
strongest
genet
associ
ms
patient
class
ii
major
histocompat
complex
mhc
specif
allel
human
leukocyt
antigen
hla
system
gene
tissu
necrosi
factor
encod
within
linkag
group
specif
differ
associ
genotyp
seen
mediterranean
popul
primarili
sardinian
haplotyp
found
associ
ms
among
ashkenazi
nonashkenazi
patient
kwon
et
al
gener
seem
exist
data
support
theori
ms
polygen
diseas
similarli
autoimmun
diseas
immun
systemrel
gene
especi
hla
region
larg
contribut
risk
develop
diseas
number
infecti
agent
report
potenti
etiolog
agent
ascherio
munger
gilden
steelman
includ
varicella
zoster
sotelo
et
al
sotelo
et
al
corona
virus
measl
epsteinbarr
herp
simplex
type
canin
distemp
virus
human
tcell
lymphotrop
viru
htlv
l
msassoci
agent
recent
chlamydia
none
confirm
idea
mainli
base
mechan
molecular
mimicri
molecular
similar
antigen
surfac
bacteria
virus
selfmyelin
protein
lead
therefor
fals
respons
myelin
genet
suscept
individu
season
variat
ms
exacerb
somehow
increas
incid
follow
vaccin
may
also
support
infecti
theori
sibley
foley
goodkin
hertsgaard
andersen
et
al
kriesel
et
al
kriesel
sibley
kneider
et
al
de
keyser
et
al
sibley
et
al
correal
et
al
banwel
et
al
edward
et
al
pohl
et
al
alotaibi
et
al
buljevac
et
al
buljevac
et
al
horakova
et
al
kvistad
et
al
lindsey
et
al
ordonez
et
al
burgoon
et
al
leibovitch
jacobson
mulvey
et
al
karussi
petrou
simpson
et
al
latter
case
vaccin
pathogenet
mechan
may
involv
bystand
activ
immun
system
due
adjuv
use
prepar
vaccin
put
time
acquisit
ms
gener
accept
puberti
patient
deduc
studi
ms
english
immigr
south
africa
note
diseas
rare
develop
immigr
age
compar
number
would
develop
england
dean
kurtzk
similar
studi
confirm
observ
support
concept
secret
femal
sex
hormon
play
import
role
enhanc
immun
respons
significantli
increas
puberti
poser
addit
fact
first
ms
sign
appear
often
puberti
shortli
data
indic
chang
activ
ms
phase
menstrual
cycl
pozzilli
et
al
support
role
hormon
milieu
addit
risk
factor
diseas
rate
relaps
ms
declin
pregnanc
especi
third
trimest
increas
first
month
postpartum
return
prepregn
rate
kornlubetzki
et
al
confavreux
et
al
coyl
runmark
andersen
support
previou
treatment
highdos
gynecolog
hormon
ivf
shown
associ
higher
risk
ms
onset
relaps
diseas
michel
et
al
investig
howev
fail
find
signific
correl
pregnanc
ms
activ
sinc
genet
alon
explain
variabl
ms
preval
like
environment
factor
also
influenc
acquisit
diseas
mani
studi
enorm
varieti
possibl
agent
factor
could
influenc
acquisit
develop
diseas
carri
variou
countri
controversi
result
usual
factor
relat
clinic
onset
rather
acquisit
ms
eber
ascherio
influenc
environment
factor
appar
consid
effect
migrat
preval
incid
rate
frenchmen
live
africa
consider
lower
preval
rate
live
franc
children
west
indian
asian
immigr
unit
kingdom
incid
preval
rate
nativeborn
englishmen
israelborn
children
ashkenazi
sephard
jew
also
preval
rate
although
parent
rate
quit
differ
hand
jewish
immigr
come
northern
european
countri
carri
much
higher
risk
ms
arriv
israel
age
year
depend
length
exposur
stagelevel
matur
immun
system
milo
kahana
kahana
et
al
alter
et
al
martinican
black
develop
ms
spent
signific
period
time
metropolitan
franc
acquir
diseas
situat
hawaii
illustr
appear
uniqu
contradictori
situat
presum
environ
exert
opposit
effect
differ
ethnic
group
alter
et
al
person
japanes
extract
live
hawaii
california
increas
risk
ms
compar
live
japan
vs
caucasian
rais
hawaii
appear
offer
protect
ms
vs
difficult
conceiv
environment
factor
dispar
effect
unless
genet
makeup
individu
also
play
role
equat
exist
premorbid
genet
marker
ms
trait
could
provid
explan
epidemiolog
studi
demonstr
primari
import
genet
factor
modifi
yet
unrecogn
environment
one
among
environment
factor
may
possibl
includ
toxic
substanc
exposur
air
pollut
irradi
stress
sunlight
exposur
may
respons
grow
incid
ms
autoimmun
gener
western
world
vitamin
seem
play
import
role
jame
et
al
smolder
et
al
salzer
et
al
salzer
et
al
variat
ms
incid
among
individu
born
certain
season
year
may
also
indic
sunlight
exposur
possibl
vitamin
level
mother
may
increas
decreas
risk
ms
newborn
children
born
april
may
found
higher
risk
develop
ms
willer
et
al
dobson
et
al
summar
pathogenet
model
basi
abovedescrib
avail
data
seem
ms
result
genet
suscept
subjectof
activ
immun
system
differ
infecti
agent
initi
pathogenet
cascad
fulli
understood
eventu
lead
destruct
myelin
axon
rather
low
rate
concord
ms
monozygot
twin
never
fulli
explain
support
possibl
multipl
factor
genet
involv
diseas
pathogenesi
genet
suscept
individu
may
develop
ms
extern
trigger
infecti
environment
trigger
onset
poser
suggest
statu
defin
ms
trait
differ
asymptomat
ms
may
never
develop
diseas
result
action
antigen
challeng
immun
system
genet
vulner
person
caus
damag
nervou
parenchyma
subsequ
environment
viralantigen
event
ms
trait
carrier
chang
trait
diseas
event
could
infect
need
symptomat
vaccin
ms
may
becom
symptomat
remain
asymptomat
manifest
lesion
visibl
mri
ri
like
develop
ms
trait
defin
activ
occur
earli
life
wherea
transit
ms
trait
ms
ie
acquisit
take
place
puberti
patient
immun
system
made
vulner
outpour
femal
sex
hormon
pattern
destruct
myelin
uniqu
ms
compar
demyelin
eg
acut
dissemin
encephalomyel
adem
dysmyelin
eg
metachromat
adrenoleukodystrophi
diseas
consist
plaqu
sharpli
demarc
normal
white
matter
surround
figur
aptli
describ
cut
cooki
cutter
contrast
inflammatori
lesion
adem
almost
invari
perivascular
often
becom
confluent
unless
pathognomon
sharp
edg
ms
lesion
captur
biopsi
sometim
imposs
clearli
differenti
adem
plaqu
commonli
seen
optic
nerv
chiasm
periventricular
centrum
semioval
brain
stem
cerebellar
hemispher
cervic
spinal
cord
although
plaqu
seen
white
matter
may
involv
subcort
ufib
extend
gray
matter
cortex
thalamu
basal
ganglia
dentat
nuclei
may
affect
lesion
sensori
nucleu
trigemin
nerv
intraparenchym
portion
facial
connect
acoust
nerv
frequent
involv
peripher
nerv
spare
asymmetri
lesion
rule
inflammatori
cellular
infiltr
edema
almost
invari
seen
wall
small
blood
vessel
surround
parenchyma
edg
plaqu
similar
chang
wall
capillari
venul
also
seen
socal
normal
appear
white
matter
nawm
ms
cn
one
earliest
chang
separ
myelin
lamella
vesicular
edema
fragment
sheath
invas
macrophag
engulf
myelin
debri
eventu
denud
axon
plaqu
show
periaxil
demyelin
axon
appear
intact
older
lesion
clearli
show
axon
neuron
degener
clump
larg
abnorm
gemistocyt
astrocyt
may
seen
near
lesion
occasion
mistaken
astrocytoma
ms
variant
marburg
acut
ms
balo
concentr
sclerosi
schilder
type
diffus
sclerosi
exhibit
similar
also
distinct
patholog
featur
poser
brinar
b
perivenular
inflammatori
lesion
involv
infiltr
mononuclear
cell
evid
earlier
phase
diseas
frohman
et
al
steinman
inflamm
lead
damag
loss
oligodendrocyt
demyelin
result
disrupt
conduct
neuron
signal
affect
region
initi
stage
ms
compensatori
pathway
upregul
ionchannel
affect
area
may
partial
restor
conduct
revers
neurolog
dysfunct
diseas
progress
signific
axon
loss
eventu
neuron
damag
occur
trapp
et
al
lost
function
becom
perman
nonrevers
steinman
trapp
et
al
grigoriadi
et
al
wide
accept
inflammatori
process
ms
caus
propag
autoimmun
cascad
figur
involv
mainli
cell
target
myelin
selfantigen
zhang
et
al
allegretta
et
al
possibl
mechan
known
molecular
mimicri
crossreact
antigen
express
virus
microorgan
myelin
compon
wucherpfennig
stroming
autoimmun
hypothesi
also
support
find
increas
incid
autoimmun
diseas
patient
ms
firstdegre
rel
barcello
et
al
ramagopalan
et
al
altern
hypothesi
myelinspecif
cell
present
natur
may
expand
critic
pathogen
quantiti
venken
et
al
due
malfunct
immunoregulatori
mechan
involv
cell
regulatori
cell
treg
although
autoimmun
hypothesi
attract
support
concret
data
includ
efficaci
immunomodulatori
treatment
ms
initi
insult
initi
whole
immunemedi
cascad
still
obscur
environment
genet
infecti
factor
seem
play
import
role
ms
pathogenesi
seem
role
put
infecti
agent
triggerdr
autoimmun
process
venken
et
al
rather
serv
primari
target
infiltr
cell
case
cell
phenotyp
specif
myelin
antigen
epitop
seem
repres
common
final
pathogenet
effector
pathway
regardless
initi
insult
diseas
tesmer
et
al
korn
et
al
kebir
et
al
follow
initi
damag
myelin
bloodbrain
barrier
open
myelinrel
antigen
releas
peripher
blood
caus
activ
anti
myelin
autoreact
product
new
antimyelin
lymphocyt
profil
tcell
receptor
recognit
probabl
chang
cours
diseas
epitop
spread
miller
quintana
et
al
howev
ms
homogen
diseas
increasingli
recogn
sever
distinct
immunopatholog
profil
includ
promin
humor
immun
mechan
ms
patient
lucchinetti
et
al
initi
stage
autoimmun
cascad
ms
probabl
initi
peripher
immun
system
follow
activ
macrophag
dendrit
cell
antigenpres
cell
apc
lymphocyt
express
antigen
specif
myelin
tcell
receptor
tcr
prolifer
begin
express
membran
adhes
molecul
chemokin
receptor
enhanc
abil
extravas
site
inflamm
cn
sharief
et
al
b
tsukada
et
al
b
c
washington
et
al
produc
interleukin
il
tumor
necrosi
factoralpha
tnfa
interferongamma
ifng
proinflammatori
cytokin
migrat
possibl
follow
damag
signal
cn
tissu
due
openingdestruct
bloodbrain
barrier
adhes
molecul
crucial
import
process
blockag
may
prevent
extravas
lymphocyt
blood
vessel
endothelium
yednock
et
al
polman
et
al
interestingli
best
exist
evid
ms
inde
autoimmun
diseas
whole
process
initi
peripheri
come
report
evid
high
efficaci
ms
rebound
ms
activ
follow
discontinu
medic
specif
block
migrat
lymphocyt
cn
natalizumab
target
molecul
innat
immun
also
shown
play
import
role
ms
pathogenesi
inflammatori
immun
cascad
gandhi
et
al
especi
dendrit
cell
well
nk
cell
mast
cell
gdt
cell
microgli
cell
mayo
et
al
specif
role
nk
cell
controversi
involv
nk
cell
pathophysiolog
autoimmun
diseas
studi
mani
year
matsumoto
et
al
zhang
et
al
actual
role
nk
cell
cn
autoimmun
still
clear
morandi
et
al
vitro
nk
cell
show
cytotox
activ
toward
oligodendrocyt
glial
cell
astrocyt
microgli
cell
inflamm
nk
cell
may
also
play
role
cn
protect
repair
cell
abil
produc
neurotroph
factor
hammarberg
et
al
sever
studi
describ
benefici
role
nk
cell
mous
rat
eae
matsumoto
et
al
zhang
et
al
galazka
et
al
huang
et
al
xu
et
al
human
decreas
cytotox
activ
circul
nk
cell
describ
clinic
relaps
ms
kastrukoff
et
al
kastrukoff
et
al
wherea
increas
nk
cell
subpopul
observ
remiss
phase
takahashi
et
al
upregul
bright
nk
cell
subset
immunomodulatori
therapi
daclizumab
bielekova
et
ifnb
sarast
et
al
cyclophosphamid
may
contribut
benefici
clinic
effect
medic
bielekova
et
al
b
cell
tradit
consid
play
secondari
produc
antibodi
may
promot
tissu
destruct
recruit
macrophag
activ
complement
pathway
hawker
addit
activ
b
cell
act
antigenspecif
apc
cell
produc
costimulatori
molecul
influenc
differenti
cell
cell
zouali
patient
ms
increas
bcell
number
cn
mainli
memori
cell
shortliv
plasmablast
cepok
et
al
plasmablast
persist
cerebrospin
fluid
csf
throughout
cours
ms
number
cell
correl
intrathec
immunoglobulin
g
igg
synthesi
oligoclon
antibodi
one
hallmark
ms
diagnosi
activ
inflammatori
diseas
cepok
et
al
owen
et
al
moreov
b
cell
plasma
cell
autoantibodi
complement
detect
ms
lesion
prinea
graham
archelo
et
al
indic
implic
demyelin
addit
indic
antibodymedi
mechan
ms
come
presenc
ectop
lymphoid
follicl
cn
patient
ms
cepok
et
al
serafini
et
al
krumbholz
et
al
magliozzi
et
al
especi
progress
diseas
appear
therefor
diseas
evolv
progress
stage
inflamm
becom
compartment
predominantli
mediat
b
cell
addit
find
may
explain
progress
ms
correl
slow
situ
inflamm
come
report
show
signific
mening
cortic
deep
gray
matter
inflammatori
lesion
predomin
progress
ms
patient
advanc
disabl
repres
bad
prognost
factor
serafini
et
al
magliozzi
et
al
ruggieri
et
al
haider
et
al
cappellani
et
al
daam
et
al
calabres
et
al
ceccarelli
et
al
neema
et
al
geurt
et
al
popescu
lucchinetti
popescu
et
al
lucchinetti
et
al
kutzelnigg
lassmann
romm
christensen
et
al
support
role
b
cell
immunopatholog
ms
provid
data
efficaci
bcelland
antibodydirect
therapi
ie
plasmapheresi
monoclon
antibodi
subgroup
ms
patient
weinshenk
et
al
kappo
et
al
hauser
et
al
involv
antibodymedi
pathogenet
mechan
particularli
pronounc
variant
cn
demyelin
diseas
neuromyelit
type
ms
neuromyel
optica
nmo
spectrum
disord
associ
antiaquaporin
antibodi
long
magnet
reson
imag
mri
lesion
cervic
spine
normal
motor
sensori
function
depend
upon
rapid
propag
nerv
impuls
along
myelin
nerv
fiber
measur
millisecond
myelin
sheath
interrupt
regular
interv
node
ranvier
axon
denud
axon
high
resist
electr
impuls
make
speed
conduct
slow
altern
mechan
take
call
saltatori
conduct
electr
impuls
jump
one
node
ranvier
next
achiev
requir
conduct
veloc
howev
distanc
avail
node
great
destruct
myelin
segment
impuls
bridg
gap
saltatori
conduct
longer
possibl
electr
impuls
must
travel
via
slow
axon
rout
figur
axon
destroy
conduct
obvious
longer
possibl
deficit
becom
perman
ms
patient
sign
symptom
appear
nerv
conduct
slow
bodi
temperatur
elev
result
either
ambient
heat
fever
latter
common
caus
pseudoexacerb
bodi
temperatur
increas
littl
c
may
suffici
caus
sign
symptom
disappear
upon
cool
past
use
diagnost
mean
hot
bath
test
sever
clinic
type
recogn
relapsingremit
primari
secondari
progress
rrm
ppm
spm
respect
karussi
lublin
investig
believ
clinic
type
repres
differ
diseas
genet
variant
ms
much
like
differ
evolut
indic
aggress
diseas
process
patient
suscept
accumul
lesion
eloqu
area
cn
mani
ms
lesion
remain
silent
number
routin
autopsi
seri
shown
asymptomat
ms
may
common
diagnos
condit
put
preval
frequent
perceiv
ppm
less
inflammatori
progress
slower
miller
leari
howev
epidemiolog
data
show
rr
diseas
turn
progress
diseas
ie
spm
usual
take
median
two
decad
onset
tremlett
et
al
rate
progress
differ
substanti
ppm
koch
et
al
koch
et
al
hard
et
al
confavreux
vukus
accept
nowaday
clear
demarc
relaps
progress
diseas
also
mix
cours
relapsingprogress
ms
rpm
accur
defin
progress
diseas
either
activ
inflammatori
ie
evid
relaps
chang
mri
nonactivedegen
lublin
gener
neg
prognost
factor
ms
predict
progress
higher
level
disabl
includ
earli
transform
spm
higher
relaps
rate
disabl
first
year
shorter
interv
first
second
relaps
earli
involv
neurolog
system
degenhardt
et
al
vukus
confavreux
symptom
ms
onset
six
seri
three
diagnosi
confirm
autopsi
diseas
almost
twice
common
women
men
clinic
onset
frequent
third
fourth
decad
certain
neurolog
complaint
person
age
tantamount
make
diagnosi
ms
lhermitt
symptom
tingl
go
back
flex
neck
trigemin
neuralgia
hemifaci
spasm
unilater
intent
tremor
binocular
diplopia
similarli
certain
abnorm
neurolog
examin
young
person
also
common
enough
ms
diagnost
valu
tempor
pallor
optic
disk
unilater
hyperreflexia
babinski
sign
signific
decreas
posit
andor
vibratori
sensat
ankl
dysmetria
fingertonos
test
internuclear
ophthalmoplegia
ms
patient
may
also
experi
rarer
symptom
headach
posit
vertigo
seizur
back
neck
pain
signific
cognit
declin
latter
thought
rare
sinc
diseas
affect
gray
matter
howev
well
document
signific
involv
gray
matter
ms
cognit
impair
frequent
even
earli
stage
diseas
deluca
et
al
langdon
chiaravalloti
deluca
cardoso
et
al
often
overseenunderdiagnos
patient
socal
benign
ms
repres
less
patient
defin
absenc
relaps
progress
disabl
year
actual
signific
silent
activ
cognit
impair
usual
affect
concentr
memori
gajofatto
et
al
correal
et
al
amato
et
al
sayao
et
al
rovari
et
al
structur
brain
damag
similar
nonbenign
ms
divers
variabl
clinic
express
sign
ms
quantifi
use
scale
disabl
univers
accept
year
expand
disabl
statu
scale
edss
initi
propos
kurtzk
revis
year
edss
step
refer
peopl
ms
abl
walk
without
aid
base
measur
impair
eight
function
system
fs
edss
step
defin
impair
walk
scale
critic
relianc
walk
main
measur
disabl
lack
linear
multipl
sclerosi
function
composit
msfc
newer
measur
system
sensit
chang
mobil
base
mainli
three
paramet
walk
speed
use
time
walk
arm
hand
dexter
use
ninehol
peg
test
cognit
function
use
pace
auditori
serial
addit
test
pasat
rudick
et
al
wide
rang
measur
use
assess
ms
disabl
mani
case
simpl
questionnair
ms
qualiti
life
fatigu
scale
questionnair
true
exacerbationsrelaps
appear
spontan
may
follow
kind
viral
infect
must
differenti
pseudoexacerb
result
fever
elev
ambient
temperatur
metabol
derang
correl
number
site
size
ms
lesion
reveal
neuroimag
autopsi
clinic
manifest
poor
mani
plaqu
involv
socal
silent
area
brain
furthermor
diseas
process
must
impair
conduct
critic
number
fiber
order
produc
neurolog
dysfunct
avail
fiber
affect
tract
number
constitut
safeti
factor
sign
symptom
due
inflamm
edema
almost
alway
case
onset
bout
revers
safeti
factor
breach
number
demyelin
destroy
fiber
exce
requir
minimum
sign
symptom
becom
perman
sever
variant
ms
cn
demyelin
syndrom
gener
nowaday
defin
karussi
effort
increas
diagnost
accuraci
identifi
uniqu
immunopathogen
profil
tabl
tailor
treatment
includ
initi
event
demyelin
defin
clinic
radiolog
isol
syndrom
ci
ri
respect
okuda
et
al
miller
et
al
b
adem
brinar
habek
meng
et
al
variant
acut
hemorrhag
leukoenceph
ahl
marburg
variant
balo
brinar
habek
concentr
sclerosi
zettl
et
al
kuperan
et
al
mader
et
al
susac
daroff
schilder
sclerosi
zettl
et
al
transvers
myeliti
poser
et
al
neuromyel
optica
nmo
nmo
spectrum
diseas
wingerchuk
weinshenk
recurr
isol
optic
neuriti
zettl
et
al
tumefact
demyelin
lucchinetti
et
al
larg
tumorlik
demyelin
lesion
surround
edema
tabl
differenti
terminolog
matter
import
implic
manag
instanc
patient
typeii
ms
immunopathogenesi
accord
luccinetti
classif
lucchinetti
et
al
autoantibodi
seem
involv
cell
neuromyelit
variant
demyelin
nmo
spectrum
diseas
associ
antiaquaporin
antibodi
wingerchuk
weinshenk
wingerchuk
et
al
wingerchuk
et
al
wingerchuk
mckay
et
al
may
respond
well
also
even
deterior
firstlin
treatment
ms
ifn
bomprezzi
et
al
uniqu
clinic
neuroradiolog
featur
tabl
along
use
immunolog
biomark
antibodi
help
distinguish
case
classic
ms
use
immunolog
imag
biomark
improv
accuraci
diagnosi
also
contribut
identif
patient
ci
ri
greater
risk
disabl
progress
wors
prognosi
contrari
benign
cours
origin
diagnost
criteria
ms
base
clinic
featur
suggest
cn
demyelin
oldest
schumach
criteria
call
two
clinic
relaps
separ
time
space
patient
age
year
better
explan
sign
symptom
schumack
et
al
subsequ
poser
criteria
ad
schumach
definit
laboratoryparaclin
paramet
diagnosi
presenc
oligoclon
band
ocbsin
csf
abnormaldelay
respons
visual
auditoryevok
potenti
poser
et
al
tabl
crucial
request
criteria
order
definit
diagnos
ms
need
clinic
laboratori
evid
dissemin
time
space
ditdi
presenc
symptom
affect
one
discret
cn
region
one
time
point
cours
diseas
patient
accordingli
subclassifi
clinic
definit
cdm
probabl
laboratorysupport
definit
probabl
ms
tabl
advanc
neuroradiolog
techniqu
mri
need
clinic
evid
dit
di
partial
replac
radiolog
evid
dissemin
base
principl
committe
head
mcdonald
defin
new
propos
criteria
mcdonald
et
al
later
revis
gener
mcdonald
criteria
focu
integr
clinic
laboratori
radiograph
data
establish
diagnosi
ms
similar
poser
criteria
mcdonald
diagnost
criteria
requir
two
clinic
attack
vari
time
space
establish
definit
diagnosi
ms
dit
could
fulfil
either
gadolinium
gd
enhanc
lesion
new
lesion
detect
repeat
mri
scan
perform
month
baselin
studi
dit
requir
either
meet
barkhoftintor
mri
criteria
criteria
gdenhanc
lesion
juxtacort
infratentori
periventricular
lesion
barkhof
et
al
tintor
et
al
presenc
two
silent
brain
lesion
ocb
csf
sensit
specif
mcdonald
criteria
predict
convers
ms
year
high
could
therefor
establish
diagnosi
ms
ci
earlier
poser
criteria
doubl
rate
ms
diagnosi
within
first
year
diseas
dalton
et
al
revis
criteria
better
underlin
signific
spinal
cord
lesion
di
criteria
allow
new
lesion
brain
mri
day
rather
previou
time
frame
month
follow
baselin
mri
establish
dit
updat
criteria
led
improv
sensit
compar
criteria
vs
retain
good
specif
vs
swanton
et
al
mcdonald
criteria
revis
intent
simplif
requir
fewer
mri
scan
establish
diagnosi
definit
ms
meet
criteria
di
patient
must
two
clinic
attack
differ
cn
site
one
clinic
attack
accompani
fulfil
swanton
radiograph
criteria
symptomat
mri
lesion
brain
stem
spinal
cord
exclud
lesion
count
mri
criteria
gd
enhanc
necessari
di
accord
criteria
dit
requir
new
gdenhanc
lesion
subsequ
mri
regardless
time
baselin
scan
presenc
asymptomat
gdenhanc
lesion
nonenhanc
lesion
baselin
mri
tabl
thu
diagnosi
ms
one
clinic
attack
may
establish
even
base
sole
baselin
mri
enhanc
nonenhanc
lesion
coexist
csf
find
replac
radiograph
requir
di
accord
mcdonald
criteria
revis
criteria
consid
increas
diagnost
sensit
without
compromis
specif
miller
et
al
involv
optic
nerv
brain
stem
spinal
cord
multifoc
brain
lesion
present
mri
mani
patient
ci
addit
abnorm
quantit
mri
otherwis
normal
appear
white
gray
matter
suggest
extens
patholog
process
miller
et
al
chronic
multifoc
demyelin
diseas
cn
clinic
andor
radiolog
evid
dissemin
time
space
usual
relaps
cours
rrm
case
cours
becom
progress
time
spm
primari
progress
preval
relapsingprogress
benign
form
also
exist
median
time
diagnosi
rrm
spm
year
time
diseas
onset
requir
cane
walk
year
patient
first
year
diseas
oligoclon
antibodi
csf
typic
acellular
normal
protein
level
brain
mri
patholog
patient
visual
andor
brain
stemevok
potenti
patholog
adem
first
ever
clinic
event
presum
inflammatori
demyelin
caus
acut
subacut
onset
affect
multifoc
area
cn
usual
polysymptomat
includ
encephalopathi
common
children
meng
et
al
caldemey
et
al
dale
et
al
mikaeloff
et
al
murthi
et
al
tardieu
mikaeloff
presenc
focalmultifoc
lesion
predominantli
affect
white
also
gray
matter
without
evid
previou
destruct
white
matter
chang
occurr
clinicalradiolog
improv
although
may
residu
deficit
absenc
etiolog
could
explain
event
new
fluctuat
symptom
sign
mri
find
occur
within
month
consid
part
initi
acut
event
lack
oligoclon
antibodi
presenc
sever
lymphocyt
csf
earli
involv
cn
gray
matter
area
lack
signific
dissemin
space
case
relaps
adem
usual
expans
previous
exist
lesion
occur
presenc
fever
confus
headach
meng
et
al
present
least
one
larg
cm
acut
demyelin
lesion
accompani
edema
mass
effect
ring
enhanc
clinic
present
vari
size
locat
lesion
often
includ
headach
confus
aphasia
apraxia
seizur
atyp
cism
lucchinetti
et
al
continu
zettl
et
al
susac
daroff
marburg
numer
larg
multifoc
demyelin
lesion
deep
white
matter
balo
concentr
layer
partial
demyelin
altern
band
demyelin
altern
isointens
hypointens
concentr
ring
imag
mri
partial
enhanc
limit
area
schilder
diseas
myelinoclast
diffus
sclerosi
usual
character
singl
two
symmetr
arrang
lesion
measur
least
cm
involv
centrum
semioval
set
symptom
unusu
ms
zettl
et
al
poser
et
al
absenc
ocb
csf
acut
hemorrhag
leukoenceph
ahl
acut
hemorrhag
leukoencephalomyel
ahem
hurst
acut
necrot
hemorrhag
leukoenceph
anhl
rare
sever
rapidli
progress
inflammatori
hemorrhag
demyelin
disord
cn
consid
variant
adem
kuperan
et
al
mader
et
al
rosman
et
al
wong
et
al
white
matter
lesion
mri
tend
larg
diffus
edema
mass
effect
well
restrict
diffus
affect
area
brain
csf
typic
demonstr
elev
wbc
red
blood
cell
protein
neuromyel
optica
nmo
episod
optic
neuriti
often
sever
bilater
lead
fix
visual
loss
acut
myeliti
major
criteria
diagnosi
contigu
spinal
mri
lesion
extend
vertebr
segment
nmoigg
seroposit
secondari
criteria
diagnosi
accord
modifi
criteria
brain
lesion
may
also
present
nmo
csf
show
pleocytosi
wbc
longitudin
extens
myelopathi
usual
affect
central
part
cord
intract
hiccup
nausea
vomit
may
report
result
periaqueduct
medullari
lesion
wingerchuk
weinshenk
wingerchuk
et
al
mckeon
et
al
clinic
sign
problem
cn
evid
two
area
cn
involv
evid
white
matter
involv
one
two
relaps
last
h
separ
least
month
progress
slow
stepwis
patient
year
age
time
examin
better
explan
patient
symptom
sign
poser
criteria
cdm
clinic
definit
ms
two
attack
relaps
clinic
neurolog
dysfunct
demonstr
neurolog
examin
paraclin
evid
demonstr
test
exist
nonclin
lesion
cn
least
one
event
clinic
evid
lsdm
laboratorysupport
definit
ms
least
one
attack
oligoclon
band
two
attack
occurr
symptom
neurolog
dysfunct
h
evid
clinic
paraclin
along
one
follow
line
one
attack
two
clinic
manifest
new
criteria
one
year
diseas
progress
retrospect
prospect
determin
two
three
follow
evid
di
brain
base
one
lesion
mscharacterist
region
periventricular
juxtacort
infratentori
evid
di
spinal
cord
base
two
lesion
cord
posit
csf
isoelectr
focus
evid
oligoclon
band
andor
elev
igg
index
mri
support
investig
diagnosi
manag
patient
ms
associ
convent
neuroradiolog
marker
clinic
disabl
ms
weak
phenomenon
refer
clinicoradiolog
paradox
miller
et
al
reason
poor
associ
includ
emphasi
mri
protocol
detect
focal
white
matter
patholog
limit
sensit
edss
score
detect
small
degre
clinic
deterior
inabl
routin
mri
techniqu
provid
accur
estim
degener
axon
damag
compartment
inflamm
ie
mening
cortic
deep
gray
matter
ruggieri
et
al
haider
et
al
cappellani
et
al
daam
et
al
calabres
et
al
neema
et
al
magliozzi
et
al
ceccarelli
et
al
geurt
et
al
popescu
lucchinetti
popescu
et
al
kutzelnigg
lassmann
serafini
et
al
lucchinetti
et
al
romm
christensen
et
al
hypointens
lesion
black
hole
seem
correl
better
measur
disabl
lesion
number
volum
venken
et
al
contrastenhanc
lesion
indic
acut
inflamm
enhanc
transient
typic
last
week
venken
et
al
lucchinetti
et
al
anoth
confound
factor
clinicoradiolog
dissoci
heterogen
lesion
ms
involv
normal
appear
white
gray
matter
correl
clinic
paramet
imag
improv
use
novel
neuroimag
techniqu
magnet
transfer
imag
function
mri
diffus
tensor
mri
rovira
et
al
wattj
et
al
techniqu
still
central
role
monitor
diseas
evolut
everyday
practic
increas
use
mr
protocol
may
provid
better
insight
diseas
activ
turn
use
inform
prognosi
guid
treatment
decis
nowaday
mri
critic
tool
diagnosi
earli
ms
mcdonald
criteria
predict
futur
cours
detect
clinic
silent
activ
ms
better
clinic
histori
neurolog
examin
alon
rudick
cutter
brain
lesion
jacob
et
al
ormerod
et
al
spinal
lesion
dalton
et
al
oriordan
et
al
develop
without
clinic
evid
relaps
new
silent
lesion
may
defin
radiolog
relaps
appear
time
frequent
lesion
associ
clinic
relaps
wingerchuk
et
al
isaac
et
al
kappo
et
al
half
ci
patient
show
one
clinic
silent
abnorm
baselin
brain
mri
miller
et
al
oriordan
et
al
brex
et
al
frohman
et
al
presenc
number
may
predict
risk
develop
ms
next
year
oriordan
et
al
kappo
et
al
ghezzi
et
al
miller
et
al
morrissey
et
al
standard
brain
mri
protocol
ms
includ
threeplan
scout
sagitt
fast
flair
axial
fast
spin
echo
proton
axial
fast
flair
axial
gdenhanc
recommend
consortium
multipl
sclerosi
center
cmsc
evalu
patient
present
possibl
ci
cmsc
guidelin
also
recommend
spinal
cord
mri
patient
present
symptom
spinal
cord
level
patient
focal
neurolog
sign
equivoc
brain
mri
result
numer
studi
assess
risk
convers
ci
cdm
suggest
patient
asymptomat
brain
mri
lesion
time
present
ci
chanc
develop
cdm
within
year
wherea
without
brain
lesion
carri
much
lower
risk
risk
frohman
et
al
beck
et
al
minneboo
et
al
scott
et
al
gener
number
lesion
seem
well
correl
risk
convers
cdm
mri
paramet
may
predict
convers
cdm
includ
presenc
multifoc
homogen
ringenhanc
white
matter
lesion
lesion
corpu
callosum
zivadinov
cox
lesion
posterolater
compart
spinal
cord
cordonni
et
al
posit
barkhof
criteria
ie
least
nine
lesion
least
one
contrastenhanc
presenc
infratentori
lesion
presenc
juctracort
lesion
least
periventricular
three
four
may
suffic
barkhof
et
al
howev
particularli
earli
stage
ms
sole
use
mri
may
introduc
diagnost
error
due
low
specif
hyperintens
lesion
white
matter
cn
sometim
defin
also
ubosunknown
bright
object
detect
plethora
patholog
condit
includ
migrain
microvascular
diseas
variou
connect
tissu
diseas
even
small
percentag
healthi
individu
kruit
et
al
morri
et
al
vernooij
et
al
reason
old
diagnost
criterion
introduc
shumack
rule
possibl
caus
still
appear
revis
criteria
mcdonald
recent
criteria
ri
stress
need
analysi
mri
data
care
perform
thorough
differenti
diagnosi
convent
imag
captur
entir
extent
ms
activ
exampl
cortic
lesion
may
exist
nearli
patient
earli
ms
lucchinetti
et
al
calabres
et
al
captur
convent
imag
doubl
invers
recoveri
imag
calabres
et
al
nelson
et
al
andor
use
mri
machin
hasan
narayana
hammond
et
al
kangarlu
et
al
mainero
et
al
presenc
least
one
cortic
lesion
patient
ci
may
help
identifi
high
risk
convers
cdm
calabres
et
al
filippi
et
al
small
studi
use
addit
advanc
mr
techniqu
magnet
reson
spectroscopi
mr
magnet
transfer
imag
mti
shown
method
contribut
predict
convers
ci
patient
cdm
wattj
et
al
b
filippi
et
al
iannucci
et
al
standard
protocol
improv
technolog
eg
softwar
seem
essenti
order
mri
use
routin
monitor
timebas
chang
brain
volum
atrophi
measur
venken
et
al
lucchinetti
et
al
visualevok
potenti
vep
abnorm
patient
ci
regardless
clinic
symptom
rot
mesec
patient
ms
bradley
et
al
histori
clinic
evid
optic
nerv
dysfunct
somatosensoryevok
potenti
ssep
brain
stem
auditoryevok
potenti
baep
may
also
use
evid
demyelin
nondetect
clinic
mri
shown
pelayo
et
al
three
evok
potenti
vep
ssep
baep
abnorm
time
ci
increas
risk
develop
moder
disabl
ms
independ
mri
find
patient
ci
ms
two
immunoglobulin
g
igg
oligoclon
band
ocb
uniqu
csf
miller
et
al
avasarala
et
al
awad
et
al
paolino
et
al
polman
et
al
sastregarriga
et
al
tintor
et
al
zipoli
et
al
csf
ocb
test
must
run
parallel
sampl
serum
obtain
within
h
lumbar
punctur
prefer
method
analysi
highest
sensit
specif
ms
isoelectr
focus
agaros
gel
follow
immunodetect
blot
fixat
freedman
et
al
ms
patient
elev
igg
index
awad
et
al
link
huang
may
conjunct
independ
presenc
ocb
csf
presenc
ocb
csf
posit
predict
valu
neg
predict
valu
sensit
specif
develop
relapsingremit
ms
rrm
ci
masjuan
et
al
presenc
ocb
within
month
ci
tintor
et
al
nearli
doubl
risk
second
clinic
attack
year
martino
et
al
hand
csf
white
blood
cell
wbc
mm
mg
dl
protein
rare
observ
ms
rais
possibl
altern
diagnosi
mcdonald
et
al
trapp
nave
also
import
bear
mind
disord
ms
may
also
associ
presenc
ocb
high
igg
index
differenti
diagnosi
presenc
ocb
csf
includ
sjogren
syndrom
patient
neurolog
involv
neurosarcoidosi
system
lupu
erythematosu
behcet
diseas
paraneoplast
disord
antiglutam
acid
decarboxylas
antibodi
syndrom
vogtkoyanagiharada
syndrom
hashimoto
steroidrespons
encephalopathi
subacut
scleros
panenceph
rubella
enceph
neurosyphili
neuroborreliosi
human
immunodefici
viru
infect
mening
adrenoleukodystrophi
ataxia
telangiectasia
leber
hereditari
optic
atrophi
cn
vascular
disord
cn
tumor
awad
et
al
ms
pathogenesi
involv
mainli
immunemedi
mechan
serum
immun
biomark
good
candid
diagnosi
prognosi
diseas
reflect
presenc
natur
intens
certain
immun
respons
hawa
et
al
also
practic
standpoint
test
serum
biomark
could
prove
use
blood
rel
simpl
collect
test
easili
repeat
monitor
strategi
schwarz
et
al
freedman
et
al
brettschneid
et
al
biomark
may
also
identifi
csf
closer
proxim
lesion
cn
biomark
conjunct
prognost
criteria
mri
may
help
earli
identif
ms
stratifi
ci
patient
accord
risk
progress
cdm
classif
rule
may
provid
addit
tool
determin
appropri
treatment
strategi
individu
patient
rudick
polman
rudick
et
al
jacob
et
al
kappo
et
al
antibodi
target
myelin
antigen
natur
one
extens
studi
serum
biomark
ms
presenc
igm
extracellular
domain
myelin
oligodentrocyt
protein
mog
togeth
antibodi
specif
myelin
basic
protein
mbp
two
main
immunogen
antigen
cn
myelin
sheath
ci
patient
shown
highli
predict
cdm
berger
et
al
tomassini
et
al
howev
studi
test
prognost
valu
antimog
antimbp
antibodi
reveal
controversi
result
rang
highli
signific
total
insignific
berger
et
al
tomassini
et
al
kuhl
et
al
b
pelayo
et
al
antibodi
target
alpha
glucosebas
antigen
found
differenti
ms
neurolog
diseas
predict
progress
sever
diseas
phenotyp
schwarz
et
al
freedman
et
al
brettschneid
et
al
recent
antibodi
novel
astrocyt
target
potassium
channel
protein
found
associ
ms
srivastava
et
al
brill
et
al
howev
associ
univers
confirm
addit
group
remain
controversi
brickshawana
et
al
bcell
chemoattract
chemokin
also
shown
serv
prognost
marker
convers
cdm
patient
ci
especi
combin
barkhof
mri
criteria
festa
et
al
alvarez
et
al
ferraro
et
al
khademi
et
al
addit
novel
biomark
ms
includ
osteopontin
tnfa
variou
cytokin
chemokin
bcrystallin
neurofila
protein
subunit
late
focu
interest
prognost
biomark
presenc
high
level
csf
may
reflect
acut
axon
damag
impli
prognost
valu
convers
ci
cdm
teunissen
khalil
teunissen
et
al
fialova
et
al
b
logic
base
wide
accept
model
ms
immunopathogenesi
describ
previous
tabl
figur
therapeut
approach
diseas
includ
modal
aim
downregul
variou
immun
element
involv
immunolog
cascad
karussi
sinc
introduct
ifn
first
regist
immunotherapi
ms
huge
step
made
field
ms
immunotherapi
novel
time
concept
immunomodul
refer
specif
downregul
pathogen
immun
cell
induct
shift
immun
respons
enhanc
intrins
regulatori
immun
network
oppos
gener
immunosuppress
initi
introduc
studi
ifn
linomid
earli
abramski
et
al
karussi
et
al
karussi
et
al
last
two
decad
sinc
advent
ifn
copaxon
targetfocus
immunoact
drug
introduc
appear
new
treatment
efficaci
figur
howev
seemingli
increas
efficaci
new
immunomodulatori
drug
care
interpret
clinic
trial
last
decad
includ
ms
patient
lower
relaps
rate
fact
complic
comparison
old
new
gener
drug
addit
safeti
issu
arisen
new
immunomodul
figur
sinc
neurodegener
evolv
earli
andprobablya
consequ
inflamm
earli
immun
intervent
warrant
prevent
relaps
diseas
also
accumul
disabl
futur
irrevers
damag
use
neuroimag
mri
techniqu
allow
detect
silent
inflammatori
activ
neurodegener
provid
import
tool
substanti
clinic
efficaci
treatment
earli
diagnosi
ms
introduct
new
diagnost
criteria
mcdonald
et
al
cdm
necessitatea
past
yearsth
occurr
second
clinic
relaps
dissemin
time
space
reflect
mri
dynam
chang
pave
path
concept
earli
immunotherapi
select
patient
experienc
first
demyelin
episod
ci
even
theoret
individu
sole
neuroradiolog
evid
demyelin
ri
howev
prognosi
ms
highli
variabl
therefor
addit
clinic
radiolog
immunolog
surrog
biomark
use
defin
case
bad
prognosi
earli
immunotherapi
stage
ci
ri
may
justifi
immunotherapeut
modal
divid
two
main
group
affect
acut
phase
relaps
diseas
longterm
prevent
treatment
immunomodul
treatment
may
also
classifi
accord
level
immun
axi
exert
main
effect
figur
tabl
base
molecular
construct
basic
mechan
action
immunotherapeut
agent
may
also
classifi
cytotox
drug
synthet
immunomodul
monoclon
antibodi
vaccin
tcell
vaccin
antigen
vaccin
oral
toler
agent
modal
act
indirect
immunosuppress
plasmapheresi
intraven
immunoglobulin
ivig
cellular
therapi
stem
cell
progenitor
wide
use
treatment
acut
ms
relaps
methylprednisolon
corticosteroid
prepar
figur
spectrum
variou
immunotherapi
ms
newer
modal
seemingli
increas
efficaci
specif
also
safeti
issu
reprint
permiss
poser
c
atla
multipl
sclerosi
parthenon
publish
group
london
fig
p
descript
mechan
action
immunotherapeut
agent
ms
class
evid
efficaci
basic
mechan
action
class
evid
efficaci
ms
corticosteroid
l
induct
synthesi
result
diminish
eicosanoid
product
l
suppress
cyclooxygenas
express
l
inhibit
gene
affect
product
cytokin
interleukin
ifng
tnfa
result
tcell
inhibit
l
downregul
antibodi
product
l
downregul
adhes
molecul
express
l
reduct
bloodbrain
barrier
bbb
permeabl
high
supraphysiolog
dose
glucocorticoid
strongli
downregul
inflamm
suppress
cellular
immun
inhibit
gene
affect
product
variou
cytokin
tnfa
reduc
prolif
abil
cell
rose
et
al
abbruzzes
et
al
barkhof
et
al
beck
et
al
miller
et
al
glucocorticoid
also
suppress
humor
immun
caus
b
cell
express
smaller
amount
receptor
thu
diminish
expans
antibodi
product
steroid
reduc
permeabl
bloodbrain
barrier
miller
et
al
kesselr
et
al
descript
mechan
action
immunotherapeut
agent
ms
class
evid
efficacydcont
cyclophosphamid
l
nitrogen
mustard
alkyl
agent
oxazophorin
group
broad
cytotox
immunosuppress
effect
main
metabolit
phosphoramid
mustard
form
cell
low
aldehyd
dehydrogenas
aldh
level
l
format
dna
crosslink
guanin
posit
lead
cell
death
l
suppress
mostli
b
cell
l
suppress
cell
ifng
cytokin
product
l
increas
product
induct
shift
corticotropin
aka
adrenocorticotrop
hormon
acth
hasten
recoveri
month
treatment
rose
et
al
compar
superior
result
shown
methylprednisolon
abbruzzes
et
al
b
barn
et
al
thompson
et
al
data
optic
neuriti
treatment
trial
show
intraven
methylprednisolon
superior
oral
prednison
treatment
acut
optic
neuriti
beck
beck
howev
longterm
effect
treatment
regimen
visual
acuiti
margin
signific
protect
later
develop
definit
ms
beck
et
al
beck
et
al
review
trial
either
intraven
methylprednisolon
acth
show
clear
benefit
steroid
ms
exacerb
filippini
et
al
patient
chronic
progress
ms
steroid
show
milder
effect
two
studi
shown
shortterm
improv
follow
highdos
intraven
methylprednisolon
cazzato
et
al
longterm
benefici
effect
intraven
methylprednisolon
boost
slow
develop
black
hole
delay
wholebrain
atrophi
disabl
progress
zivadinov
et
al
despit
data
document
transient
benefici
effect
acut
ms
relaps
steroid
seem
significantli
alter
natur
cours
diseas
chronic
use
seem
justifi
addit
chronic
steroid
administr
associ
sever
advers
effect
includ
osteoporosi
asept
bone
necrosi
hypertens
hyperglycemia
cataract
psychot
event
despit
wide
agreement
efficaci
steroid
treatment
ms
relaps
optim
protocol
administr
drug
still
settl
current
protocol
mostli
empir
includ
even
day
g
intraven
methylprednisolon
without
oral
taper
prednison
oral
administr
highdos
methylprednisolon
appear
equal
effici
intraven
administr
alam
et
al
sellebjerg
et
al
martinelli
et
al
indic
base
publish
studi
ms
experi
autoimmun
diseas
system
lupu
erythematosu
sle
abrupt
discontinu
intraven
steroid
treatment
ms
relaps
may
increas
risk
recurr
symptom
therefor
taperingoff
protocol
follow
highdos
intraven
methylprednisolon
appear
prefer
level
b
activ
proliferationexpans
autoimmun
myelin
reactiv
lymphocyt
chemotherapeuticcytotox
agent
azathiorpin
cyclophosphamid
methotrex
cyclosporin
mycophenol
cladribin
mitoxantron
tarcolimu
teriflunomid
immunoabl
reset
immun
system
hematopoiet
stem
cell
transplant
lymphocyt
deplet
monoclon
antibodi
alemtuzumab
rituximab
daclizumab
specif
reduct
autoimmun
myelinrespons
lymphocyt
vaccin
techniqu
ie
tcell
vaccin
myelin
peptid
vaccin
level
c
regulatori
cell
immunolog
shift
ifnb
ga
laquinimod
fingolimod
alemtuzumab
teriflunomid
cyclophosphamid
level
e
b
cell
antibodieshumor
immun
plasmapheresi
ivig
monoclon
antibodi
steroid
cytotox
drug
azathiorpin
mycophenol
cyclopshosphamid
alemtuzumab
level
b
g
cytokin
product
variou
immunosuppress
corticosteroid
ifnb
ga
fingolimod
teriflunomid
cyclosporinea
laquinimod
cyclophosphamid
azathioprin
alemtuzumab
level
f
migrat
home
lymphocyt
entranc
bloodbrain
barrier
fingolimod
natalizumab
corticosteroid
question
effect
mild
effect
moder
effect
strong
effect
neg
effect
borderlin
effect
plasmapheresi
also
known
therapeut
plasma
exchang
plex
procedur
separ
blood
compon
exchang
plasma
typic
donor
plasma
albumin
return
compon
primarili
red
blood
cell
patient
plex
known
effect
variou
autoimmun
diseas
sinc
late
plex
tri
sever
studi
ms
patient
inconsist
effect
may
relat
small
size
studi
lack
homogen
treatment
protocol
use
plex
adjuv
therapi
immunomodulatori
modal
patient
popul
typecours
ms
greatli
vari
among
studi
khatri
et
al
canadian
cooper
multipl
sclerosi
studi
group
noseworthi
et
al
weiner
et
al
recent
random
trial
repres
reviv
plex
treatment
modal
ms
plex
first
time
check
singl
modal
patient
variou
type
acut
cn
demyelin
diseas
includ
acut
dissemin
encephalomyel
neuromyelit
type
ms
nmo
spectrum
disord
either
chronic
relaps
weinshenk
et
al
clinic
improv
note
plextreat
patient
compar
sham
group
followup
studi
keegan
et
al
suggest
patient
myeliti
pattern
ii
immunopathogenesi
accord
lucchinetti
et
al
predominantli
antibodymedi
diseas
best
respons
plex
recent
retrospect
analysi
patient
treat
plex
steroidrefractori
cn
demyelin
episod
show
exhibit
moder
mark
function
neurolog
improv
within
month
follow
treatment
magana
et
al
logic
sinc
nmo
correspond
typeii
histopatholog
phenotyp
ms
lesion
nmo
patient
expect
optim
respons
plex
inde
two
small
open
studi
retrospect
one
nmo
patient
acut
attack
diseas
show
earli
signific
improv
follow
plex
treat
patient
wang
et
al
watanab
et
al
bonnan
et
al
american
academi
neurolog
task
committe
upon
evalu
neurolog
indic
plex
gave
level
b
recommend
use
secondlin
treatment
steroidresist
exacerb
relaps
form
ms
nmo
cortes
et
al
first
gener
old
player
typei
ifn
ifna
ifnb
first
use
ground
antivir
activ
could
possibl
help
elimin
put
viral
agent
involv
ms
pathogenesi
howev
initi
trial
ifng
type
ii
show
treatment
actual
promot
relaps
ms
panitch
et
al
ifnb
hand
intrathec
subcutan
induc
benefici
effect
patient
ms
jacob
et
al
panitch
et
al
ifnb
shown
inhibit
tcell
activ
enhanc
suppressor
cell
activ
reduc
ifng
product
mhcii
express
increas
product
downregul
antigen
present
induc
shift
reduc
permeabl
bloodbrain
barrier
dhibjalbut
mark
first
pivot
doubleblind
trial
recombin
betaferon
scheringbay
given
subcutan
everi
day
report
reduc
relaps
rate
without
significantli
affect
disabl
statu
ifnb
multipl
sclerosi
studi
group
ifnbtreat
patient
significantli
lower
mri
burden
diseas
reduct
activ
scan
pati
li
treatment
gener
well
toler
except
flulik
symptom
fever
chill
myalgia
fatigu
occur
major
patient
tend
decreas
first
month
treatment
injectionsit
irrit
also
common
second
studi
recombin
glycosyl
avonex
biogen
dose
miu
intramuscularli
per
week
induc
reduct
relaps
rate
similar
betaferon
rate
treatment
also
result
decreas
number
volum
gddtpaenhanc
lesion
mri
delay
sustain
progress
disabl
jacob
et
al
third
type
recombin
rebif
merkserono
million
iu
subcutan
everi
day
prism
studi
group
reduc
relaps
risk
delay
progress
disabl
suppress
mri
activ
li
pati
benefici
effect
ifnb
shown
longlast
freedman
eber
et
al
earli
treatment
ifnb
ci
patient
show
reduc
risk
convers
cdm
year
jacob
et
al
filippi
et
al
kappo
et
al
compar
studi
comi
et
al
show
cumul
probabl
mcdonald
definit
ms
significantli
lower
patient
treat
stronger
benefici
effect
higherfrequ
regimen
rebif
systemat
review
efficaci
ifn
ms
conclud
evid
rrm
mainli
term
reduct
relaps
frequenc
first
less
second
year
treatment
convinc
efficaci
thereaft
effect
accumul
disabl
rice
et
al
data
efficaci
ifnb
progress
ms
conflict
one
european
studi
show
betaferon
significantli
increas
month
time
confirm
diseas
progress
becom
wheelchair
bound
compar
placebo
patient
spm
european
studi
group
hand
north
american
trial
spm
fail
show
benefici
effect
medic
betaferon
diseas
progress
panitch
et
al
benefit
secondari
outcom
measur
differ
found
outcom
two
studi
remain
puzzl
kappo
et
al
might
relat
differ
popul
ms
patient
includ
two
trial
anoth
trial
test
spm
signific
effect
disabl
progress
suppress
superimpos
relaps
mri
activ
prism
studi
group
final
studi
third
type
commerci
ifn
avonex
patient
spm
although
differ
edss
detect
signific
benefici
effect
multipl
sclerosi
function
composit
msfc
scale
relapserel
paramet
ppm
two
random
control
trial
fail
show
benefici
effect
ifnb
diseas
progress
roja
et
al
leari
thompson
montalban
et
al
differ
favor
treatment
observ
msfc
sever
secondari
mri
paramet
three
studi
compar
efficaci
regist
ifn
report
greater
efficaci
highdos
ifnb
rebif
betaferon
lower
dose
avonex
trial
rather
small
short
durat
comi
et
al
panitch
et
al
durelli
et
al
hand
anoth
trial
cadavid
et
al
show
signific
differ
betaferon
avonex
outcom
kochhenriksen
et
al
ifnbtreat
patient
develop
persist
neutral
antibodi
usual
first
year
treatment
commonli
receiv
presenc
usual
associ
reduct
treatment
effect
malucchi
et
al
franci
et
al
hartung
et
al
goodin
et
al
pachner
et
al
glatiram
acet
ga
copaxon
teva
israel
synthet
copolym
compos
alanin
glutamin
lysin
tyrosin
immunolog
similar
mbp
molecul
myelin
antigen
without
encephalitogen
ga
presum
block
mhctcr
complex
downregul
antigen
present
cell
competit
inhibit
andor
induc
regulatori
cell
rack
et
al
pilot
control
studi
bornstein
et
al
patient
rrm
great
reduct
number
relaps
gatreat
group
report
later
larger
pivot
doubleblind
trial
johnson
et
al
show
ga
induc
reduct
relaps
rate
without
affect
progress
disabl
year
mri
monitor
perform
one
center
show
margin
inhibit
mri
activ
advers
effect
usual
mild
includ
mainli
local
injectionsit
reaction
system
reaction
occur
within
moment
ga
administr
associ
chest
pain
palpit
dyspnea
patient
separ
random
studi
treatment
ga
led
signific
reduct
total
number
enhanc
lesion
compar
placebo
comi
et
al
patient
treat
year
ga
maintain
improv
unchang
edss
score
low
annual
relaps
rate
karussi
et
al
ga
also
shown
reduc
risk
ci
patient
develop
cdm
trial
ga
ppm
termin
interim
analysi
indic
discern
treatment
effect
primari
outcom
sajja
et
al
oral
prepar
ga
shown
ineffect
evalu
later
larg
trial
includ
filippi
et
al
two
compar
trial
ga
ifnb
differ
clinic
mri
paramet
observ
treatment
group
cadavid
et
al
oconnor
et
al
mikol
et
al
data
open
pilot
control
studi
indic
intraven
immunoglobulin
ivig
efficaci
reduc
number
relaps
progress
disabl
rrm
achiron
et
al
fazeka
et
al
b
howev
two
trial
fail
show
efficaci
treatment
patient
rrm
progress
ms
cook
et
al
franci
et
al
mri
monitor
latter
trial
reveal
effect
ivig
treatment
prevent
appear
new
lesion
brain
arnold
et
al
spm
two
studi
homm
et
al
pohlau
et
al
fail
show
benefici
effect
ppm
singl
studi
report
significantli
less
patient
edss
progress
ivigtr
group
placebo
group
nonsignific
trend
delay
time
diseas
progress
pohlau
et
al
mri
data
report
two
rrm
studi
lewanska
et
al
fazeka
et
al
one
spm
homm
et
al
conflict
convinc
addit
trial
clinic
mri
endpoint
signific
differ
report
placebo
ivigtreat
group
sorensen
et
al
howev
studi
suffer
consider
methodolog
difficulti
particularli
respect
blind
alloc
conceal
two
addit
trial
noseworthi
et
al
achiron
et
al
rigor
methodolog
qualiti
entir
neg
across
wide
rang
clinic
paraclin
outcom
measur
infusionrel
side
effect
report
particip
treat
ivig
fazeka
et
al
homm
et
al
achiron
et
al
one
studi
report
six
particip
deep
venou
thrombosi
four
also
develop
pulmonari
embol
treatment
group
ivig
poorli
toler
one
trial
fazeka
et
al
experienc
sever
cutan
reaction
studi
one
case
hepat
c
viral
infect
one
mortal
pulmonari
embolu
fazeka
et
al
homm
et
al
pohlau
et
al
achiron
et
al
sever
immunosuppress
treatment
tri
ms
past
decad
variabl
efficaci
azathioprin
antimetabolit
broad
spectrum
immunosuppress
effect
one
main
immunosuppress
cytotox
substanc
avail
use
extens
control
transplant
reject
prevent
clonal
expans
lymphocyt
affect
cellular
humor
immun
azathioprin
test
pilot
clinic
trial
achiron
et
al
british
dutch
multipl
sclerosi
azathioprin
trial
group
goodkin
et
al
british
dutch
multipl
sclerosi
trial
shown
reduc
rate
progress
year
total
azathioprin
test
five
control
trial
achiron
et
al
british
dutch
multipl
sclerosi
azathioprin
trial
group
goodkin
et
al
relaps
remit
ms
patient
patient
progress
diseas
includ
five
trial
almost
half
includ
patient
suffer
progress
diseas
analysi
cumul
data
patient
five
trial
show
treatment
azathioprin
caus
rel
relaps
risk
reduct
year
respect
casetta
et
al
proport
patient
progress
year
treatment
lower
azathioprin
group
one
small
studi
massacesi
et
al
reduct
gadoliniumenhanc
lesion
lesion
observ
patient
treat
azathioprin
side
effect
azathioprin
includ
gastrointestin
discomfort
pain
cutan
rash
incid
liver
enzym
elev
macrocyt
anemia
occur
azathioprinetr
patient
small
insignific
absolut
increas
risk
malign
cours
azathioprin
slightli
increas
mortal
rate
azathioprin
group
taylor
et
al
cyclophosphamid
alkyl
drug
bind
dna
interfer
mitosi
cell
replic
suppress
thu
cellular
humor
immun
cyclophosphamid
commonli
use
antineoplast
drug
treatment
sever
system
autoimmun
disord
initi
pilot
open
studi
back
earli
show
posit
indic
efficaci
cyclophosphamid
ms
trial
open
uncontrol
homm
et
al
two
larg
random
trial
report
conflict
result
weiner
et
al
benefici
effect
observ
first
seen
mainli
young
patient
differ
stabil
rate
small
disappear
month
latter
canadian
cooper
multipl
sclerosi
studi
group
signific
differ
time
worsen
edss
sinc
earli
sever
trial
case
report
cyclophosphamid
patient
rapidli
worsen
treatmentrefractori
ms
show
gener
moder
benefici
clinic
neuroradiolog
effect
activ
diseas
hohol
et
al
khan
et
al
perini
gallo
zephir
et
al
de
bittencourt
gomesdasilva
gobbini
et
al
combin
cyclophosphamid
reduc
clinic
diseas
activ
gadoliniumenhanc
mri
lesion
brain
patti
et
al
cyclophosphamid
caus
sever
side
effect
includ
alopecia
nausea
vomit
hemorrhag
cystiti
leukopenia
myocard
infertil
pulmonari
interstiti
fibrosi
mitoxantron
anthracenedion
antineoplast
drug
intercal
dna
inhibit
dna
rna
synthesi
mitoxantron
inhibit
bcell
function
includ
antibodi
secret
abat
helper
cytotox
tcell
activ
decreas
secret
cytokin
ifng
tnfa
fox
first
placebocontrol
trial
mitoxantron
show
signific
reduct
annual
relaps
rate
increas
proport
patient
relapsefre
differ
edss
score
millefiorini
et
al
subsequ
phase
iii
trial
patient
worsen
rrm
spm
hartung
et
al
higher
dose
mg
q
month
mitoxantron
significantli
effect
combin
clinic
outcom
measur
consist
five
clinic
paramet
chang
edss
chang
ambul
index
number
treat
relaps
time
firsttreat
relaps
chang
neurolog
statu
addit
mitoxantron
ifnbtreat
patient
decreas
mean
frequenc
volum
gadoliniumenhanc
lesion
relaps
rate
jefferi
et
al
similar
benefici
effect
observ
also
mitoxantron
ad
ga
ramtah
et
al
mitoxantron
licens
cytotox
medic
ms
patient
spm
progress
relaps
worsen
rrm
use
confin
case
suffici
aggress
ms
justifi
toxic
effect
mitoxantron
caus
cardiotox
cumul
allow
dose
exceed
mg
acut
leukemia
aml
cumul
risk
advers
effect
methotrex
folic
acid
analog
potent
immunosuppress
whose
mode
action
predominantli
inhibit
thymidin
biosynthesi
although
antiinflammatori
effect
reli
upon
specif
mechan
inhibit
purin
pyrimidin
synthesi
methotrex
suppress
tcell
prolifer
promot
adenosinemedi
inflamm
use
treatment
autoimmun
diseas
transplant
placebocontrol
studi
methotrex
low
dose
report
mild
benefici
effect
composit
measur
edss
ambul
index
two
arm
function
test
progress
ms
gray
et
al
goodkin
et
al
effect
methotrex
mri
activ
also
margin
anoth
trial
methotrex
currier
et
al
show
differ
edss
progress
progress
group
recent
studi
sadiq
et
al
investig
intrathec
administr
methotrex
progress
ms
patient
seriou
advers
effect
note
studi
period
spm
patient
edss
score
stabl
improv
gener
methotrex
toxic
usual
low
treatment
parallel
folat
substitut
howev
longterm
methotrex
administr
may
associ
seriou
side
effect
includ
hepatotox
hepat
fibrosi
cyclosporina
cyclic
fungal
peptid
inhibit
calcineurin
similar
aspect
tacrolimu
one
wide
administ
immunosuppress
drug
cyclosporin
studi
multicent
doubleblind
clinic
trial
involv
progress
ms
patient
multipl
sclerosi
studi
group
mean
increas
edss
ae
cyclosporinetr
patient
ae
placebo
group
cyclosporin
delay
time
becom
wheelchair
bound
rel
risk
statist
signific
time
sustain
progress
high
rate
hypertens
nephrotox
induc
treatment
limit
use
along
increas
risk
malign
skin
cancer
cladribin
synthet
purin
nucleosid
analog
preferenti
accumul
lymphocyt
disturb
dna
synthesi
repair
mechan
result
lymphocyt
deplet
longlast
lymphopenia
cladribin
penetr
cn
interact
cell
peripher
circul
cn
use
firstlin
treatment
hairi
cell
leukemia
older
studi
total
patient
shown
efficaci
parenter
cladribin
rrm
progress
ms
clinic
mri
paramet
sipe
et
al
beutler
et
al
larg
recent
phase
iii
trial
new
prepar
oral
cladribin
two
dose
new
treatment
scheme
test
patient
rrm
giovannoni
et
al
significantli
lower
annual
relaps
rate
cladribin
group
compar
placebo
group
lower
risk
sustain
progress
disabl
parallel
reduct
number
brain
lesion
mri
advers
event
includ
lymphocytopenia
herp
zoster
infect
neoplasm
aros
treat
patient
mycophenol
mofetil
mmf
belong
antimetabolit
drug
class
prodrug
activ
metabolit
mycophenol
acid
inhibit
tand
bcell
prolifer
henc
immunoglobulin
ig
product
mmf
also
suppress
dendrit
cell
matur
decreas
capac
antigen
present
lymphocyt
small
trial
progress
ms
suggest
efficaci
mmf
administr
appear
well
toler
frohman
et
al
ahren
et
al
addit
openlabel
trial
combin
mmf
exhibit
superior
efficaci
compar
alon
vermersch
et
al
retrospect
trial
mmf
shown
prevent
relaps
nmo
patient
jacob
et
al
advers
event
includ
benign
infecti
diseas
insomnia
dizzi
nausea
abdomin
pain
still
control
larg
studi
mmf
ms
bacteri
product
bind
immunophilin
way
prevent
cell
transit
phase
cell
cycl
drug
potent
cyclosporin
less
pronounc
side
effect
use
primarili
transplant
pilot
clinic
trial
lemster
et
al
tacrolimu
chronic
progress
ms
show
overal
degre
disabl
deterior
significantli
patient
studi
month
tacrolimu
administr
rational
combin
immunotherapi
review
conway
cohen
come
report
synergist
effect
increas
efficaci
combin
immunomodulatori
agent
autoimmun
diseas
breedveld
et
al
also
justifi
acknowledg
complex
ms
immunopathogenesi
may
necessit
use
one
drug
interfer
variou
distinct
immun
element
involv
multipl
level
immun
axi
order
maxim
treatment
efficaci
figur
howev
owe
complex
interact
delic
balanc
variou
immun
cell
cytokin
chemokin
network
unexpect
paradox
effect
may
occur
differ
drug
affect
immun
system
combin
smallsiz
open
studi
provid
posit
indic
support
principl
combin
treatment
methotrex
azathioprin
plu
ifnb
calabresi
et
al
pulicken
et
al
howev
larger
control
studi
use
ifn
basic
therapi
methotrex
steroid
azathioprin
addon
neg
show
trend
havrdova
et
al
cohen
et
al
ravnborg
et
al
except
one
sorensen
et
al
show
benefit
combin
ifn
steroid
combin
natalizumab
ifnb
show
addit
benefit
reduct
relaps
rate
trial
termin
two
case
progress
multifoc
leukoencephalopathi
pml
natalizumabavonex
combin
group
goodman
et
al
addit
ga
natalizumab
improv
neuroradilog
endpoint
trial
addit
benefit
term
relaps
edss
chang
goodman
et
al
random
doubleblind
placebocontrol
trial
cyclophosphamid
addon
therapi
ifnb
singleblindcontrol
trial
reveal
benefit
addit
cyclophosphamid
without
steroid
ifnb
patti
et
al
smith
et
al
treatment
strategi
entail
rescu
therapeut
scheme
strong
immunosuppress
cyclophosphamid
mitoxantron
follow
mainten
treatment
ifn
ga
suggest
show
promis
result
patti
et
al
jefferi
et
al
ramtah
et
al
edan
et
al
combin
simvastatin
cholesterollow
agent
put
immunomodulatori
neuroprotect
properti
offer
addit
benefici
effect
sorensen
et
al
monoclon
antibodi
mab
monospecif
antibodi
made
ident
immun
cell
clone
uniqu
parent
cell
contrast
polyclon
antibodi
made
sever
differ
immun
cell
monoclon
antibodi
monoval
affin
bind
antigen
epitop
biolog
synthes
mab
target
precis
defin
antigen
like
magic
bullet
repres
whole
new
categori
timmunotherapeut
drug
natalizumab
target
surfac
molecul
crucial
transmigr
lymphocyt
bbb
cn
monthli
infus
antibodi
show
strong
efficaci
placebo
reduc
relaps
rate
year
chanc
acquir
fix
disabl
year
moreov
natalizumabtr
patient
free
diseas
activ
relaps
progress
disabl
new
mri
activ
around
although
efficaci
appear
higher
observ
ifn
ga
pivot
studi
cross
comparison
differ
studi
differ
design
ms
patient
popul
scientif
sound
us
european
author
licens
natalizumab
relaps
ms
drug
later
withdrawn
market
two
case
pml
progress
multifoc
leucoenceph
almost
univers
lethal
infect
identifi
trial
combin
avonex
natalizumab
rudick
et
al
result
natalizumab
licens
monotherapi
sever
rrm
secondlin
immunotherapi
ms
sinc
licens
mani
addit
case
pml
identifi
almost
exclus
among
patient
treat
year
natalizumab
three
paramet
identifi
relat
increas
risk
pml
durat
treatment
previou
exposur
cytotox
medic
presenc
antijc
john
cunningham
viru
antibodi
found
half
ms
patient
indic
previou
exposur
viru
sorensen
et
al
report
case
pml
follow
natalizumab
treatment
posit
jc
viru
antibodi
introduct
test
antibodi
help
select
patient
treat
natalizumab
treatment
discontinu
due
high
risk
ie
case
three
risk
factor
pml
alemtuzumab
human
monoclon
antibodi
target
antigen
b
lymphocyt
klotz
et
al
produc
rapid
sustain
lymphocyt
deplet
approv
therapi
bcell
chronic
lymphocyt
leukemia
first
trial
alemtuzumab
rrm
suspend
immun
thrombocytopen
purpura
develop
three
patient
one
die
studi
alemtuzumab
treatment
reduc
relaps
rate
compar
chanc
accumul
disabl
year
mri
outcom
also
signific
favor
alemtuzumab
advers
event
alemtuzumab
group
includ
autoimmun
thyroid
disord
immun
thrombocytopen
purpura
infect
two
consequ
larg
phase
iii
trial
conclud
rrm
show
reduct
relaps
rate
group
treat
two
annual
cycl
alemtuzumab
compar
rebif
year
reduct
risk
sustain
accumul
disabl
cole
et
al
side
effect
alemtuzumab
includ
high
incid
autoimmun
diseas
especi
autoimmun
thrombocytopenia
thyroid
cossburn
et
al
rituximabocrelizumab
accumul
evid
involv
b
lymphocyt
pathophysiolog
ms
pave
way
bcelldirect
therapi
lassmann
bcell
deplet
affect
antibodi
product
cytokin
network
bcellmedi
antigen
present
activ
cell
macrophag
rituximab
genet
engin
chimer
murinehuman
monoclon
antibodi
target
antigen
express
preb
matur
b
cell
rituximab
shown
signific
efficaci
suppress
sever
autoimmun
disord
system
lupu
erythematosu
sle
rheumatoid
arthriti
two
pilot
open
studi
ms
patient
test
effect
two
cours
rituximab
mg
month
apart
mg
weekli
week
seriou
advers
event
note
except
mildtomoder
infusionassoci
reaction
fewer
new
gadoliniumenhanc
lesion
seen
rituximabtr
patient
associ
appar
reduct
relaps
baror
et
al
naismith
et
al
random
phase
ii
doubleblind
trial
treatment
rituximab
mg
given
everi
month
led
signific
reduct
gadoliniumenhanc
lesion
seen
mri
lesion
volum
compar
placebo
patient
rituximab
group
lower
annual
rate
relaps
hauser
et
al
rituximab
treatment
also
evalu
patient
ppm
hawker
et
al
patient
receiv
two
mg
intraven
rituximab
placebo
infus
everi
week
week
cours
differ
two
group
term
time
confirm
diseas
progress
signific
although
rituximab
patient
significantli
lower
increas
lesion
volum
subgroup
analysi
show
signific
differ
time
confirm
diseas
progress
patient
age
year
gadoliniumenhanc
lesion
compar
placebo
advers
event
compar
group
howev
seriou
infect
occur
rituximab
placebo
patient
anoth
total
human
monoclon
antibodi
ocrelizumab
also
test
recent
patient
rrm
larg
multicent
random
doubleblind
placebocontrol
studi
week
number
gadoliniumenhanc
lesion
lower
mg
ocrelizumab
group
placebo
group
lower
mg
group
similarli
pronounc
effect
secondari
relapserel
outcom
recent
present
data
two
larg
doubleblind
trial
shown
signific
efficaci
treatment
ocrelizumab
relaps
ms
ppm
medic
shown
signific
efficaci
ppm
daclizumab
target
cell
surfac
receptor
express
activ
tlymphocyt
import
immun
system
regul
necessari
clone
expans
surviv
activ
tlymphocyt
daclizumab
act
bind
receptor
achain
prevent
clonal
expans
activ
lymphocyt
shorten
surviv
use
prophylaxi
acut
organ
reject
bilater
kidney
transplant
side
effect
pilot
studi
daclizumab
provid
indic
efficaci
reduc
gadoliniumenhanc
lesion
ms
patient
van
oosten
et
al
wynn
et
al
bielekova
et
al
accompani
signific
expans
natur
killer
nk
cell
peripher
blood
csf
first
doubleblind
phase
iii
trial
placebo
annual
relaps
rate
lower
patient
given
daclizumab
hyp
mg
subcutan
everi
week
reduct
mg
reduct
given
placebo
slightli
patient
daclizumab
group
seriou
advers
event
exclud
ms
relaps
gold
et
al
recent
report
phase
iii
trial
patient
treat
daclizumab
significantli
lower
annual
relaps
rate
treat
number
new
newli
enlarg
hyperintens
lesion
mri
also
lower
daclizumab
group
kappo
et
al
fingolimod
gilenya
novarti
switzerland
modul
receptor
strong
immunoregulatori
properti
sinc
receptor
intern
appear
crucial
step
migrat
lymphocyt
neutral
pathway
inhibit
egress
cell
b
cell
lymph
node
result
two
phase
iii
studi
patient
rrm
kappo
et
al
cohen
et
al
show
efficaci
fingolimod
placebo
clear
superior
accept
safeti
profil
arr
reduc
fingolimod
mg
group
compar
placebo
compar
fingolimod
also
significantli
reduc
cumul
probabl
confirm
disabl
progress
show
superior
secondari
mrirel
endpoint
fda
approv
fingolimod
firstlin
treatment
rrm
wherea
european
medicin
agenc
ema
restrict
use
secondlin
treatment
firstlin
treatment
patient
activ
diseas
fingolimod
treatment
caus
signific
lymphopenia
effect
circul
lymphocyt
revers
cell
count
return
normal
within
week
cessat
treatment
advers
event
relat
fingolimod
includ
bradycardia
atrioventricular
conduct
block
start
fingolimod
administr
macular
edema
elev
liver
enzym
level
lymphocytopenia
hypertens
rel
rare
longterm
safeti
data
warrant
teriflunomid
activ
metabolit
leflunomid
approv
use
patient
rheumatoid
arthriti
reduc
activ
mitochondri
enzym
dihydroorot
dehydrogenas
crucial
pyrimidin
synthesi
tlymphocyt
prolifer
larg
depend
pyrimidin
synthesi
random
control
phase
iii
trial
patient
activ
rrm
teriflunomid
dose
mg
significantli
lower
arr
similar
degre
rate
disabl
worsen
superior
drug
versu
placebo
confirm
rang
mri
endpoint
teriflunomid
dose
well
toler
although
diarrhea
nausea
liver
enzym
elev
record
teriflunomid
suggest
teratogen
hepatotox
myelosuppress
effect
result
headtohead
trial
vermersch
et
al
reveal
statist
superior
rebif
teriflunomid
arm
risk
treatment
failur
primari
composit
endpoint
studi
drug
trade
name
aubagio
licens
fda
ema
dimethyl
fumar
oral
formul
dimethyl
fumar
induc
activ
nuclear
factor
pathway
protect
oxid
stressrel
neuron
death
damag
myelin
cn
sever
neuroprotect
antiinflammatori
mechan
attribut
drug
express
phase
ii
detoxif
enzym
astrogli
microgli
cell
druginduc
shift
toward
antiinflammatori
cytokin
profil
pilot
studi
patient
rrm
oral
formul
fumar
acid
fumaderm
biogen
idec
approv
germani
treatment
psoriasi
reduc
number
gadoliniumenhanc
lesion
brain
mri
scan
schimrigk
et
al
subsequ
phase
iib
studi
rrm
show
mg
three
time
daili
reduc
number
gadoliniumenhanc
new
lesion
larg
phase
iii
trial
show
mg
twice
three
time
daili
reduc
arr
number
gadoliniumenhanc
lesion
new
enlarg
lesion
compar
placebo
group
cumul
probabl
confirm
edss
worsen
lower
new
signific
safeti
issu
report
gold
et
al
anoth
phase
iii
parallelcompar
trial
annual
relaps
rate
significantli
lower
group
gatreat
arm
placebo
group
reduct
disabl
progress
signific
either
medic
ga
similar
benefici
effect
compar
placebo
term
reduc
mri
activ
advers
event
associ
includ
flush
gastrointestin
event
diarrhea
nausea
upper
abdomin
pain
well
decreas
lymphocyt
count
elev
liver
enzym
level
lymphocyt
count
tend
decreas
chronic
lymphopen
patient
seem
increas
risk
pml
addit
yet
approv
oral
immunomodulatori
drug
laquinimod
deriv
linomid
effect
suppress
eae
strong
clinic
effect
ms
shown
phase
iii
studi
comi
et
al
reduc
arr
edss
worsen
loss
brain
volum
year
second
phase
iii
studi
vollmer
et
al
fail
reveal
benefici
effect
relaps
rate
compar
placebo
induc
benefici
effect
edss
progress
brain
volum
loss
tcell
vaccin
tcv
first
introduc
eae
rat
model
use
activ
irradi
mbpspecif
tcell
line
clone
bennun
et
al
rational
vaccin
attenu
myelinrespons
cell
induc
immun
respons
cell
probabl
one
respons
inflamm
demyelin
ms
zhang
et
al
small
phase
ii
clinic
trial
tcv
variou
stage
ms
alreadi
report
literatur
correal
et
al
herman
et
al
herman
et
al
medaer
et
al
stinissen
et
al
zhang
vandenbark
abulafialapid
achiron
mandel
studi
show
consist
reduct
mbpspecif
cell
follow
tcv
reveal
indic
clinic
efficaci
similar
approach
vaccin
relev
antimyelin
antigenrespons
bourdett
et
al
tcell
receptor
vandenbark
et
al
use
vaccin
contain
alter
myelin
peptid
kappo
et
al
anoth
uniqu
approach
specif
downregul
myelinreact
lymphocyt
consid
main
respond
cell
induct
demyelin
util
oral
toler
techniqu
faria
weiner
initi
smallscal
doubleblind
trial
earli
rrm
patient
show
trend
better
clinic
outcom
reduct
mbpreactiv
cell
myelintr
patient
without
advers
effect
weiner
et
al
hohol
et
al
howev
phase
iii
trial
confirm
efficaci
therapi
slightli
differ
approach
involv
administr
synthet
peptid
deriv
sequenc
mbp
intrathec
intraven
rout
use
attempt
toler
patient
catz
warren
et
al
goodkin
et
al
hematopoiet
stem
cell
transplant
hsct
ms
autoimmun
diseas
gener
base
principl
radic
suppress
immun
system
abrog
inflammatori
pathogenet
process
ms
subsequ
reset
immun
system
scratch
autolog
set
usual
use
immun
system
reconstitut
patient
stem
cell
rational
type
therapeut
approach
ms
deriv
pivot
anim
studi
perform
back
earli
karussi
et
al
open
uncontrol
clinic
trial
shown
impress
effect
suppress
inflamm
induct
remiss
stabil
ms
fassa
et
al
curro
et
al
nash
et
al
burt
et
al
mancardi
et
al
worldwid
patient
ms
treat
hsct
review
differ
condit
protocol
use
studi
complic
uniform
interpret
data
gener
overal
surviv
rate
progressionfre
surviv
record
mean
transplantationrel
mortal
rang
pivot
studi
neuron
stem
cell
shown
signific
benefici
clinic
effect
mice
eae
anim
model
ms
benhur
et
al
pluchino
et
al
subsequ
embryon
type
adult
stem
cell
especi
mesenchym
stem
cell
msc
test
variou
model
eae
nicoletti
et
al
kassi
et
al
aharonowiz
et
al
msc
inject
either
intraven
csf
strongli
suppress
clinic
patholog
sign
eae
revers
disabl
importantli
remyelin
evid
msctreat
anim
accompani
impress
neuroprotect
kassi
et
al
addit
scientif
rational
use
msc
eae
ms
deriv
report
strong
immunomodulatori
effect
cell
nauta
fibb
uccelli
et
al
uccelli
et
al
phase
iii
safeti
studi
msc
bone
marrowderiv
cell
perform
ms
karussi
et
al
yamout
et
al
overal
msc
given
intraven
intrathec
well
toler
preliminari
evid
efficaci
connick
et
al
specif
immunotherapi
regist
ms
sinc
introduct
ifnb
huge
step
made
increasingli
specif
efficaci
figur
modal
introduc
regist
howev
along
seemingli
increas
efficaci
newli
introduc
target
immunotherapi
safeti
issu
arisen
cumul
experi
obtain
numer
clinic
trial
ms
variou
type
immunotherapi
allow
one
draw
conclus
inflamm
probabl
initi
peripher
immun
system
crucial
format
new
demyelin
lesion
time
appear
main
caus
result
axon
damag
neuron
tissu
atrophi
immunolog
therapi
ideal
appli
earli
possibl
might
prevent
progress
disabl
given
cascad
event
lead
irrevers
tissu
loss
report
lower
efficaci
known
immunotherapi
patient
progress
form
ms
might
explain
possibl
inflamm
less
pronounc
compartment
cn
stage
diseas
effect
modal
exert
strong
local
immunomodul
cn
might
benefici
progress
ms
addit
goal
futur
ms
therapi
includ
neuroprotect
modal
techniqu
may
enhanc
neuroregener
remyelin
high
expect
direct
focus
stem
cellrel
treatment
substanti
futur
control
trial
final
import
emphasis
ms
homogen
diseas
distinct
type
immun
pathogenesi
seem
involv
differ
subgroup
lucchinetti
et
al
use
neuroimag
immunolog
biomark
would
help
tailorperson
immunotherapi
individu
case
manag
symptom
ms
poser
brinar
spastic
pain
usual
neuralg
sphincter
abnorm
fatigu
memori
declin
depress
walk
difficulti
receiv
less
attent
compar
diseasemodifi
treatment
howev
effect
symptom
qualiti
life
profound
interest
pharmacolog
treatment
symptom
ms
increas
recent
year
sever
larg
random
control
trial
report
control
trial
proven
efficaci
modafinil
brioschi
et
al
moller
et
al
amantadin
ledinek
et
al
fatigu
fampridin
improv
walk
abil
motor
function
reduc
spastic
allart
et
al
goodman
et
al
keun
et
al
medic
use
control
pain
usual
neuralg
pain
trigemin
neuralgia
includ
antiepilept
drug
carbamazepin
lamotrigin
gabapentin
hydantoin
antidepress
medic
amitriptylin
thompson
et
al
zajicek
apostu
baclophen
either
oral
use
intrathec
pump
lead
medic
use
control
spastic
also
tizanidin
medic
cannabi
dantrolen
shown
efficaci
unit
kingdom
tizanidin
trial
group
haselkorn
et
al
lakhan
rowland
montalban
rekand
gron
schmidt
et
al
stien
et
al
vaney
et
al
wade
et
al
urinari
problem
manag
variou
medic
depend
type
dysfunct
ie
urinari
detrusor
overact
urinari
retent
dyssynergia
bladder
includ
anticholinerg
ditropan
ablock
combin
pharmacolog
strategi
core
compon
treatment
ms
symptom
imper
rememb
multidisciplinari
rehabilit
approach
need
effect
manag
